CEMI - Chembio Diagnostics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.02
+0.81 (+13.04%)
At close: 4:00PM EDT

7.12 +0.10 (1.42%)
Pre-Market: 9:15AM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.21
Open6.26
Bid0.00 x 1000
Ask7.45 x 1200
Day's Range5.86 - 7.25
52 Week Range2.25 - 8.00
Volume1,006,470
Avg. Volume535,440
Market Cap124.49M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateMar 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Chembio Receives Second UNICEF Order for $1.5 Million

      HAUPPAUGE, N.Y., April 08, 2020 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced a.

    • Company News for Apr 2, 2020
      Zacks

      Company News for Apr 2, 2020

      Companies In The News Are: CEMI, DPW, MEDS, INSG

    • The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
      Benzinga

      The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

      Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NASDAQ: FTSV) * Ra Pharmaceuticals Inc (NASDAQ: RARX) * Quidel Corporation (NASDAQ: QDEL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) * Aikido Pharma Inc (NASDAQ: AIKI) * BIOLASE Inc (NASDAQ: BIOL) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * Gritstone Oncology Inc (NASDAQ: GRTS) * Neovasc Inc (NASDAQ: NVCN)(moved in reaction to its fourth quarter results) * Opko Health Inc. (NASDAQ: OPK) * Phio Pharmaceuticals Corp (NASDAQ: PHIO)(announced $4 million registered offering) * Second Sight Medical Products Inc (NASDAQ: EYES)Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning JudgmentStocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX) said it has enrolled and dosed the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, its monoclonal anti-C5a antibody in patients with severe COVID-19-induced pneumonia. The trial is being initiated in the Netherlands.The decision to initiate human testing follows initial positive human data from two patients suffering from COVID-19-induced pneumonia, who were treated with BDB-001, an anti-C5a antibody produced from BDB from the IFX-1 cell line, in China.The company said it plans to initiate additional centers in Germany and potentially other European countries.In pre-market trading Wednesday, InflaRx shares were jumping 114.66% to $8.20.Emergent Biosolutions To Provide CDMO Services For Novavax's Flu Vaccine Candidate Novavax, Inc. (NASDAQ: NVAX) and Emergent Biosolutions Inc (NYSE: EBS) announced an agreement, whereby the latter would provide molecule-to-market contract development and manufacturing to produce the former's recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.Novavax recently announced positive results for the late-stage trial that evaluated the vaccine candidate.Novavax shares were adding 3.09% to $14 in pre-market trading.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Mesoblast's Regulatory Filing For Graft Vs. Host Disease Drug Accepted For Priority Review Mesoblast limited (NASDAQ: MESO) said the FDA has accepted for priority review its BLA for Ryoncil, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease. The PDUFA date has been set for Sept. 30, the company noted.View more earnings on IFRXThe stock was advancing 8.45% to $4.75 in pre-market trading.Eisai To Co-develop And Commercialize Seikagaku's Osteoarthritis Drug In China Eisai Co., Ltd (OTC: ESALY) announced an agreement with Seikagaku for co-developing and marketing of SI-613 in China. SI-613 is a therapeutic agent for osteoarthritis discovered by Seikagaku.Chembio Launches Serological COVID-19 Detection Test In U.S. Chembio Diagnostics Inc (NASDAQ: CEMI) said it has launched in the U.S. the rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies."These results can be obtained within 15 minutes from a simple finger stick utilizing Chembio's MicroReader 1 and MicroReader 2 analyzers which are produced by Chembio Germany," the company said.The stock was jumping 23.05% to $6.30 in after-hours trading.Becton Dickinson Releases COVID-19 Test Developed By BioMedomics Medtech company Becton Dickinson and Co (NYSE: BDX) and privately held diagnostics company BioMedomics announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes.The new test developed and manufactured by BioMedomics will be available through BD and distributed exclusively by Henry Schein, Inc. (NASDAQ: HSIC) to health care providers throughout the U.S.BD shares were adding 0.97% to $232 in pre-market trading.Ultragenyx Out-licenses Gene Therapy Platforms And In-licenses Gene Therapy Vectors Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) announced a strategic partnership and non-exclusive license and technology access agreement with DAIICHI SANKYO/S ADR (OTC: DSNKY) for its AAV-based gene therapy manufacturing technologies, namely its HeLa PCL and HEK293 transient transfection manufacturing technology platforms.The agreement provides for Daiichi Sankyo making an upfront payment of $125 million and an equity investment amounting to $75 million at about $60 per share in Ultragenyx. Daiichi Sankyo will pay an additional $25 million upon completion of the technology transfer of the HeLa PCL and HEK293 platforms as well as single-digit royalties on net sales of products manufactured in either system.Separately, Ultragenyx and Regenxbio Inc (NASDAQ: RGNX) announced a new exclusive, worldwide license agreement, extending the companies' existing gene therapy partnership. Under the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to its NAV AAV8 and AAV9 vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder. Regenxbio will be compensated with an upfront payment of $7 million, ongoing fees, milestone payments, and royalties on net sales of products incorporating the licensed intellectual property.On The Radar Earnings Ascendis Pharma A/S (NASDAQ: ASND) (after the market close)See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • GlobeNewswire

      Chembio Announces Launch of DPP COVID-19 Serological Point-of-Care Test

      Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the U.S. launch of the rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies. The ability of the DPP platform to provide numerical results can aid clinicians in determining current or past exposure to the COVID-19 virus and monitoring infection progression, while avoiding the human interpretation errors associated with visual readings.

    • GlobeNewswire

      Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

      HAUPPAUGE, N.Y., March 20, 2020 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in.

    • GlobeNewswire

      Chembio Diagnostics Receives $4 Million Purchase Order from Bio-Manguinhos for Production of DPP COVID-19 IgM/IgG System in Brazil

      Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced its receipt of a $4 million order from Bio-Manguinhos for the purchase of Chembio’s DPP COVID-19 IgM/IgG System, to support the urgent needs of Brazil’s Ministry of Health. Bio-Manguinhos is a subsidiary of the Oswaldo Cruz Foundation (Fiocruz) that is responsible for the development and production of vaccines, diagnostics and biopharmaceuticals, primarily to meet demands of Brazil’s national public health system.

    • Chembio Diagnostics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
      Simply Wall St.

      Chembio Diagnostics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates

      There's been a major selloff in Chembio Diagnostics, Inc. (NASDAQ:CEMI) shares in the week since it released its...

    • Thomson Reuters StreetEvents

      Edited Transcript of CEMI earnings conference call or presentation 12-Mar-20 8:30pm GMT

      Q4 2019 Chembio Diagnostics Inc Earnings Call

    • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
      Benzinga

      The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

      Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Achieve Life Sciences Inc (NASDAQ: ACHV) * Acorda Therapeutics Inc (NASDAQ: ACOR) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * ADMA Biologics Inc (NASDAQ: ADMA) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Aileron Therapeutics Inc (NASDAQ: ALRN) * Aimmune Therapeutics Inc (NASDAQ: AIMT) * Akari Therapeutics PLC (NASDAQ: AKTX) * Akcea Therapeutics Inc (NASDAQ: AKCA) * Akero Therapeutics Inc (NASDAQ: AKRO) * Akers Biosciences Inc (NASDAQ: AKER) * Akorn, Inc. (NASDAQ: AKRX) * Albireo Pharma Inc (NASDAQ: ALBO) * Alcon AG (NYSE: ALC) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Alkermes Plc (NASDAQ: ALKS) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) * Amarin Corporation plc (NASDAQ: AMRN) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP) * Anixa Biosciences Inc (NASDAQ: ANIX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Applied DNA Sciences Inc (NASDAQ: APDN) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Aptinyx Inc (NASDAQ: APTX) * Aquestive Therapeutics Inc (NASDAQ: AQST) * Aravive Inc (NASDAQ: ARAV) * Arca Biopharma Inc (NASDAQ: ABIO) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Artelo Biosciences Inc (NASDAQ: ARTL) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * Atossa Therapeutics Inc (NASDAQ: ATOS) * aTyr Pharma Inc (NASDAQ: LIFE) * Auris Medical Holding Ltd (NASDAQ: EARS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * Avanos Medical Inc (NYSE: AVNS) * AVEO Pharmaceuticals, Inc. ((NASDAQ: AVEO) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * AzurRx BioPharma Inc (NASDAQ: AZRX) * Bausch Health Companies Inc (NYSE: BHC) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * Bio-Path Holdings Inc (NASDAQ: BPTH) * BIO-TECHNE Corp (NASDAQ: TECH) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BioLife Solutions Inc (NASDAQ: BLFS) * BIOLINERX LTD/S ADR (NASDAQ: BLRX) * BioNano Genomics Inc (NASDAQ: BNGO) * BioSig Technologies Inc (NASDAQ: BSGM) * BioTelemetry Inc (NASDAQ: BEAT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * bluebird bio Inc (NASDAQ: BLUE) * Blueprint Medicines Corp (NASDAQ: BPMC) * Boston Scientific Corporation (NYSE: BSX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Cara Therapeutics Inc (NASDAQ: CARA) * Cardiovascular Systems Inc (NASDAQ: CSII) * CareDx Inc (NASDAQ: CDNA) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Catalyst Biosciences Inc (NASDAQ: CBIO) * Celcuity Inc (NASDAQ: CELC) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cellect Biotechnology Ltd - ADR (NASDAQ: APOP) * CELYAD SA/ADR (NASDAQ: CYAD) * Cerecor Inc (NASDAQ: CERC) * Champions Oncology Inc (NASDAQ: CSBR) * Checkpoint Therapeutics Inc (NASDAQ: CKPT) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Chiasma Inc (NASDAQ: CHMA) * CNS Pharmaceuticals Inc (NASDAQ: CNSP) * Codexis, Inc. (NASDAQ: CDXS) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) * Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) * Curis, Inc. (NASDAQ: CRIS) * CytomX Therapeutics Inc (NASDAQ: CTMX) * DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) * DelMar Pharmaceuticals Inc (NASDAQ: DMPI) * Denali Therapeutics Inc (NASDAQ: DNLI) * Dynavax Technologies Corporation (NASDAQ: DVAX) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) * Edap Tms SA (NASDAQ: EDAP) * Edesa Biotech Inc (NASDAQ: EDSA) * Editas Medicine Inc (NASDAQ: EDIT) * Ekso Bionics Holdings Inc (NASDAQ: EKSO) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Elanco Animal Health Inc (NYSE: ELAN) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Enochian Biosciences Inc (NASDAQ: ENOB) * Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evelo Biosciences Inc (NASDAQ: EVLO) * Evogene Ltd (NASDAQ: EVGN) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exicure Inc (NASDAQ: XCUR) * Eyenovia Inc (NASDAQ: EYEN) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * FibroGen Inc (NASDAQ: FGEN) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Forward Pharma A/S (NASDAQ: FWP) * FSD Pharma Inc (NASDAQ: HUGE) * G1 Therapeutics Inc (NASDAQ: GTHX) * Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) * Genocea Biosciences Inc (NASDAQ: GNCA) * Geron Corporation (NASDAQ: GERN) * Glaukos Corp (NYSE: GKOS) * GlaxoSmithKline plc (NYSE: GSK) * Globus Medical Inc (NYSE: GMED) * GlycoMimetics Inc (NASDAQ: GLYC) * Gossamer Bio Inc (NASDAQ: GOSS) * Grifols SA - ADR ADR Class B (NASDAQ: GRFS) * Gritstone Oncology Inc (NASDAQ: GRTS) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Hepion Pharmaceuticals Inc (NASDAQ: HEPA) * Heron Therapeutics Inc (NASDAQ: HRTX) * Hologic, Inc. (NASDAQ: HOLX) * Ideaya Biosciences Inc (NASDAQ: IDYA) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Illumina, Inc. (NASDAQ: ILMN) * ImmuCell Corporation (NASDAQ: ICCC) * Immunomedics, Inc. (NASDAQ: IMMU * Incyte Corporation (NASDAQ: INCY * INmune Bio Inc (NASDAQ: INMB * INNATE PHARMA S/S ADR (NASDAQ: IPHA * Innovate Biopharmaceuticals Inc (NASDAQ: INNT * Intec Pharma Ltd (NASDAQ: NTEC * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Ionis Pharmaceuticals Inc (NASDAQ: IONS) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV * Jaguar Health Inc (NASDAQ: JAGX) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Johnson & Johnson (NYSE: JNJ) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Kalvista Pharmaceuticals Inc (NASDAQ: KALV) * Kamada Ltd. (NASDAQ: KMDA) * KemPharm Inc (NASDAQ: KMPH) * KITOV PHARMA LT/S ADR (NASDAQ: KTOV) * Kura Oncology Inc (NASDAQ: KURA) * Laboratory Corp. of America Holdings (NYSE: LH) * Lantheus Holdings Inc (NASDAQ: LNTH) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * LogicBio Therapeutics Inc (NASDAQ: LOGC) * MacroGenics Inc (NASDAQ: MGNX) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Magenta Therapeutics Inc (NASDAQ: MGTA) * MannKind Corporation (NASDAQ: MNKD) * TapImmune Inc. common stock (NASDAQ: MRKR) * MediciNova, Inc. (NASDAQ: MNOV) * Medigus Ltd. (NASDAQ: MDGS) * Mediwound Ltd (NASDAQ: MDWD) * MEI Pharma Inc (NASDAQ: MEIP) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Menlo Therapeutics Inc (NASDAQ: MNLO) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Monopar Therapeutics Inc (NASDAQ: MNPR) * Mustang Bio Inc (NASDAQ: MBIO) * Mylan NV (NASDAQ: MYL) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Nektar Therapeutics (NASDAQ: NKTR) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * NewLink Genetics Corp (NASDAQ: NLNK) * Novartis AG (NYSE: NVS) * Novus Therapeutics Inc (NASDAQ: NVUS) * NuVasive, Inc. (NASDAQ: NUVA) * Obalon Therapeutics Inc (NASDAQ: OBLN) * Obseva SA (NASDAQ: OBSV) * OncoSec Medical Inc (NASDAQ: ONCS) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Orthofix Medical Inc (NASDAQ: OFIX) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Pacific Biosciences of California (NASDAQ: PACB) * Pacira Biosciences Inc (NASDAQ: PCRX) * Passage Bio Inc (NASDAQ: PASG) * PDS Biotechnology Corp (NASDAQ: PDSB) * Pfizer Inc. (NYSE: PFE) * PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) * Phio Pharmaceuticals Corp (NASDAQ: PHIO) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) * Pluristem Therapeutics Inc. (NASDAQ: PSTI) * Plus Therapeutics Inc (NASDAQ: PSTV) * Polarityte Inc (NASDAQ: PTE) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * PPD Inc (NASDAQ: PPD) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Precision BioSciences Inc (NASDAQ: DTIL) * Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) * Psychemedics Corp. (NASDAQ: PMD) * Pulse Biosciences Inc (NASDAQ: PLSE) * Radius Health Inc (NASDAQ: RDUS) * Regenxbio Inc (NASDAQ: RGNX) * Revolution Medicines Inc (NASDAQ: RVMD) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX) * Sangamo Therapeutics Inc (NASDAQ: SGMO) * SCYNEXIS Inc (NASDAQ: SCYX) * Seelos Therapeutics Inc (NASDAQ: SEEL) * Sellas Life Sciences Group Inc (NASDAQ: SLS) * Seneca Biopharma Inc (NASDAQ: SNCA) * Sesen Bio Inc (NASDAQ: SESN) * Shockwave Medical Inc (NASDAQ: SWAV) * SI-Bone Inc (NASDAQ: SIBN) * Solid Biosciences Inc (NASDAQ: SLDB) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * Spero Therapeutics Inc (NASDAQ: SPRO) * Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * Stoke Therapeutics Inc (NASDAQ: STOK) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * SurModics, Inc. (NASDAQ: SRDX) * Sutro Biopharma Inc (NASDAQ: STRO) * Synlogic Inc (NASDAQ: SYBX) * T2 Biosystems Inc (NASDAQ: TTOO) * TAIWAN LIPOSOME/S ADR (NASDAQ: TLC) * Takeda Pharmaceutical Co Ltd (NYSE: TAK) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TELA Bio Inc (NASDAQ: TELA) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tenax Therapeutics Inc (NASDAQ: TENX) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * TherapeuticsMD Inc (NASDAQ: TXMD) * Therapix Biosciences Ltd - ADR (NASDAQ: TRPX) * Theratechnologies Inc (NASDAQ: THTX) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Trevi Therapeutics Inc (NASDAQ: TRVI) * Unity Biotechnology Inc (NASDAQ: UBX) * Unum Therapeutics Inc (NASDAQ: UMRX) * Urogen Pharma Ltd (NASDAQ: URGN) * Varian Medical Systems, Inc. (NYSE: VAR) * Veracyte Inc (NASDAQ: VCYT) * Vericel Corp (NASDAQ: VCEL) * Verrica Pharmaceuticals Inc (NASDAQ: VRCA) * Viking Therapeutics Inc (NASDAQ: VKTX) * Viveve Medical Inc (NASDAQ: VIVE) * VIVUS, Inc. (NASDAQ: VVUS) * Voyager Therapeutics Inc (NASDAQ: VYGR) * Xencor Inc (NASDAQ: XNCR) * Xenetic Biosciences Inc (NASDAQ: XBIO) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zimmer Biomet Holdings Inc (NYSE: ZBH) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) * Zosano Pharma Corp (NASDAQ: ZSAN) * Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Roche's Coronavirus Test Granted Emergency Use Authorization By FDA Roche Holdings AG Basel ADR (OTC: RHHBY) said the FDA has issued an Emergency Use Authorization for the cobas SARS-CoV-2 Test, which is intended for the qualitative detection of the virus that causes COVID-19 disease in nasopharyngeal and oropharyngeal swab samples collected from patients who meet the clinical and/or epidemiological criteria for testing.The CE-IVD test is also available in markets that accept the CE mark, the company said.Bio-Rad Launches SARS-CoV-2 Standard To Validate Assays Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) said it has launched a SARS-CoV-2 Standard through its Exact Diagnostics product line to support laboratory assay validation of testing for COVID-19. This, according to the company, will help labs validate their COVID-19 assay results and accelerate access to testing.Lilly, AbCellera To Partner For COVID-19 Treatment AbCellera, a privately held company developing therapeutic antibodies, and Eli Lilly And Co (NYSE: LLY) said they have entered into an agreement to co-develop antibody products for treating COVID-19. AbCellera will leverage its rapid pandemic response platform, while Lilly will provide its global capabilities for rapid development, manufacturing and distribution.AbCellera said it has identified 500 unique fully human antibody sequences following the screening of over 5 million immune cells, while looking for ones that produced functional antibodies in the blood sample from one of the first U.S. patients who recovered.Chembio Appoints Industry Veteran Richard Eberly As CEO Chembio Diagnostics Inc (NASDAQ: CEMI) appointed diagnostics industry veteran Richard Eberly as president and CEO effective March 16. He will take over from Gail Page, who had been serving as interim CEO since January. Separately, the company said its total fourth-quarter net revenues fell 11.8% year-over-year to $6.9 million and the net loss per share widened from 20 cents to 23 cents, while analysts expected a loss of 24 cents per share.The stock was trading 17.86% higher at $3.30 in Friday's premarket session. RA Medical Appoints Will MacGuire as CEO RA Medical Systems Inc (NYSE: RMED) announced the appointment of Will MacGuire as CEO and a member of the board effective March 30. MacGuire will take over the reins from Andrew Jackson, which had occupied the post on an interim basis since August 2019\. Jackson, meanwhile, will remain as CFO.Earnings Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a vaccine against SARS-CoV-2, reported revenue of $279,000 for the fourth quarter compared to $2.5 million in the year-ago quarter. The net loss per share widened from 34 cents to 38 cents, while analysts expected a loss of 24 cents per share.The stock was slipping 19.79% to $7.62 in the premarket session. Synlogic Inc's (NASDAQ: SYBX) net loss narrowed from 48 cents per share in the fourth quarter of 2018 to 37 cents per share in the fourth quarter of 2019. Analysts had estimated a loss of 44 cents per share for the quarter.The stock rose 7.91% to $1.50 in after-hours trading.View more earnings on IBBBellicum Pharmaceuticals Inc (NASDAQ: BLCM) said its fourth-quarter revenues climbed from $300,000 in 2018 to $5.1 million in 2019. The net loss per share narrowed from $6.72 to $5.82, which was wider than the $4-per-share loss estimated by analysts.The stock plunged 15.23% to $5.01 in after-hours trading.Lineage Cell Therapeutics Inc's (NYSE: LCTX) fourth quarter revenues increased from $800,000 in 2018 to $1.2 million in 2019. The net loss per share narrowed notably from 35 cents to 3 cents, while analysts had estimated a loss of 5 cents per share.The stock gained 7.34% to 73 cents in after-hours trading.Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) reported a net loss of 29 cents per share on revenues of $300,000 for the fourth quarter of 2019. In the year ago quarter, revenues were $800,000 and the net loss per share was 46 cents. The bottom-line result was better than the consensus loss estimate of 33 cents per share.The stock lost 11.76% to 90 cents in after-hours trading.Ocular Therapeutix Inc's (NASDAQ: OCUL) fourth-quarter net product revenues increased from $504,000 in 2018 to $2.26 million in 2019, but the loss widened from 42 cents per share to 53 cents per share. Analysts had called for a loss of 45 cents per share for the quarter.The stock moved up 7.93% to $4.63 in after-hours tradingOn The Radar Earnings * PLx Pharma Inc (NASDAQ: PLXP) (before the market open) * Achieve Life Sciences Inc (NASDAQ: ACHV) (before the market open) * Neos Therapeutics Inc (NASDAQ: NEOS) (before the market open)Related Link: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues See more from Benzinga * The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • GlobeNewswire

      Chembio Diagnostics Appoints Richard Eberly As Chief Executive Officer

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Richard Eberly as its President and Chief Executive Officer effective March 16, 2020. Mr. Eberly also will be a director nominee for election at Chembio’s 2020 Annual Meeting of Stockholders. Gail Page, a Chembio director who has served as Chembio’s Interim CEO since early January 2020, will assume an active advisory role for ninety days to assist in the leadership transition.

    • GlobeNewswire

      Chembio Diagnostics Reports Fourth Quarter and Full Year 2019 Financial Results

      HAUPPAUGE, N.Y., March 12, 2020 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported.

    • GlobeNewswire

      Chembio and LumiraDx Announce COVID-19 Strategic Partnership

      Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that it has entered into a worldwide strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus and IgM and IgG antibodies on both the LumiraDx and Chembio DPP platforms. "We are very excited to join with LumiraDx in this strategic partnership, which demonstrates our scientific expertise and the versatility of our DPP platform,” stated Gail Page, Chembio's Interim Chief Executive Officer.

    • GlobeNewswire

      Chembio Diagnostics and Takeda Pharmaceutical Complete Feasibility Study

      MEDFORD, N.Y., March 11, 2020 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it.

    • GlobeNewswire

      Chembio Diagnostics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2019 after the close of trading on Thursday, March 12, 2020. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

    • GlobeNewswire

      Chembio Diagnostics Provides Update on Regulatory Status of DPP HIV-Syphilis System

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, is providing an update on the FDA Premarket Approval (PMA) application for Chembio’s DPP HIV-Syphilis Assay System. The FDA has confirmed that, of the items that had been open for the PMA review, the Syphilis arm of the study was acceptable, as were the results as they relate to the inclusion of pregnant women. As indicated by the FDA on February 21, 2020, the only remaining item requested of the company is to repeat the reproducibility study, as one of the sites in the trial reported greater variability compared to the other sites.

    • Health Check: How Prudently Does Chembio Diagnostics (NASDAQ:CEMI) Use Debt?
      Simply Wall St.

      Health Check: How Prudently Does Chembio Diagnostics (NASDAQ:CEMI) Use Debt?

      Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

    • GlobeNewswire

      Chembio Diagnostics Receives $1.5 Million UNICEF Order for Multiplex Zika Systems

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced a $1.5 million purchase order from UNICEF for multiplex Zika tests and Micro Readers following the successful completion of conditions set forth in the previously announced long term arrangement (LTA). This initial order is part of the LTA, which has a total opportunity of up to $3.5 million. Chembio’s multiplex DPP Zika System allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika virus, which is important for both treatment and surveillance.

    • GlobeNewswire

      T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer

      T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Board of Directors has appointed diagnostics industry veteran John Sperzel as President and Chief Executive Officer (CEO), effective immediately. Mr. Sperzel, who will also join the Board of Directors, succeeds John McDonough, who will continue with his Board leadership role serving as non-Executive Chairman. “I am honored to join T2 Biosystems as its second CEO at this important transitional moment,” said Mr. Sperzel.

    • GlobeNewswire

      Chembio Diagnostics Announces CEO Transition

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced President and Chief Executive Officer John Sperzel has resigned for another opportunity. The Chembio Board of Directors has appointed Director Gail Page as Interim CEO and initiated an executive search process to identify a permanent CEO. Gail Page has served on the Chembio Board of Directors since 2017.

    • Benzinga

      The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

      Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...

    • GlobeNewswire

      Chembio Diagnostics Provides Update on FDA Submission of DPP HIV-Syphilis Test

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today provided an update on its Premarket Approval application submission to the U.S. Food and Drug Administration (FDA) for the DPP HIV-Syphilis System. The company anticipates FDA approval of the DPP HIV-Syphilis System, which includes the DPP HIV-Syphilis test and DPP Micro Reader, during the first quarter of 2020.

    • How Chembio Diagnostics, Inc. (NASDAQ:CEMI) Can Impact Your Portfolio Volatility
      Simply Wall St.

      How Chembio Diagnostics, Inc. (NASDAQ:CEMI) Can Impact Your Portfolio Volatility

      Anyone researching Chembio Diagnostics, Inc. (NASDAQ:CEMI) might want to consider the historical volatility of the...

    • Should You Avoid Chembio Diagnostics Inc (CEMI) Too?
      Insider Monkey

      Should You Avoid Chembio Diagnostics Inc (CEMI) Too?

      Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]

    • Thomson Reuters StreetEvents

      Edited Transcript of CEMI earnings conference call or presentation 7-Nov-19 9:30pm GMT

      Q3 2019 Chembio Diagnostics Inc Earnings Call

    • GlobeNewswire

      Chembio Diagnostics Completes Acquisition of Orangelife

      Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has completed its previously announced acquisition of Orangelife Comercio e Industria Ltda., a Brazilian manufacturer and distributor of point-of-care diagnostics tests for infectious diseases. “Our acquisition of Orangelife strategically broadens our commercialization by enhancing our presence in Brazil, which we view as one of the most attractive infectious disease testing markets in the world,” said John Sperzel, Chembio’s Chief Executive Officer. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases.